Genesis Drug Discovery & Development, the contract research division of Genesis Biotechnology Group, has named Olesia Buiakova as its new chief scientific officer, it was reported yesterday.

In this capacity, as an expansion of Dr Buiakova's current role, she will be responsible for managing the entire integrated Genesis Drug Discovery & Development range of drug discovery services from target validation and assay development to identification of clinical candidates. She will provide leadership, oversight and coordination for the development and management of new preclinical drug discovery platforms in oncology, immunology, metabolic and ocular diseases.

Dr Buiakova started her career with Genesis Biotechnology Group as the vice president of Biology for Invivotek in 2013. Later that year, she transitioned into her current role as chief scientific officer. Prior to joining Genesis Biotechnology Group, she held multiple positions in the field of in vivo pharmacology including director at Taconic CRO Division. She was also responsible for generating animal models of human diseases at Columbia Genome Centre at Columbia University, New York, New York.